SSauvageau Lab

Achievements

30 years of translational hematology

Pioneering the genetic and epigenetic control of stem cells, redefining acute myeloid leukemia, and translating discoveries into global clinical trials.

30+

Years of translational hematology

123+

Patients transplanted internationally

~700

Primary AML specimens mapped

132

Trainees mentored worldwide

UM171: Uncovering a New Pathway to Human Blood Stem Cell Self-Renewal

Our laboratory’s work on UM171 connects fundamental discovery with clinical translation. Working closely with Anne Marinier and her medicinal chemistry team at IRIC, we discovered UM171, a small molecule that enables the expansion of human cord-blood stem cells (Fares et al., Science, 2014). We subsequently identified CRL3–KBTBD4 as the essential machinery mediating UM171-induced degradation of the CoREST complex and MYC and provided early evidence that UM171 enhances its association with KBTBD4 (Chagraoui et al., Cell Stem Cell, 2021; Blood 2025). These findings established a mechanistic foundation for subsequent structural studies by other teams that resolved the interface involving KBTBD4 and HDAC1/2. In close collaboration with Sandra Cohen and her clinical colleagues at Hôpital Maisonneuve-Rosemont, and with additional clinical investigators and partners and ExCellThera, we helped translate this discovery into transplantation trials, from the initial phase I/II study (Cohen et al., The Lancet Haematology, 2020) to two single-arm phase II studies reporting encouraging engraftment and disease-control outcomes (Cohen et al., medRxiv, 2026, submitted). This shared effort brings together stem-cell biology, medicinal chemistry and clinical expertise to create new treatment possibilities for patients with blood cancers.

A visual briefing of our impact

The highlights below trace the lab’s journey from fundamental stem cell biology to bench-to-bedside therapies. Download the full briefing to explore every milestone in detail.

30 Years of Translational Hematology

30 Years of Translational Hematology

Three decades pioneering the genetic and epigenetic control of stem cells, redefining acute myeloid leukemia (AML), and translating discoveries into global clinical trials.

Two research engines, one legacy

Two research engines, one legacy

From HSC basic biology to ex vivo expansion and clinical gene editing (123+ patients transplanted), and from the Leucegene program through multi-omics to drug discovery (~700 AML specimens mapped) — supported by 132 trainees mentored over 30 years.

Defining the framework of HSC self-renewal

Defining the framework of HSC self-renewal

Identification of HOXB4 and the polycomb gene BMI1 as essential regulators, a genetic screen uncovering 19 distinct nuclear factors and chromatin modifiers, and the central role of asymmetric cell division in stem cell biology.

From screen to clinic: the UM171 breakthrough

From screen to clinic: the UM171 breakthrough

A chemical screen for cord blood HSC expansion led to the discovery and nanomolar optimization of UM171 (Science, 2014), Phase I/II trials with 123+ patients, EMA approval (Aug 2025), and the ExCellThera spin-out.

Unlocking the mechanism for clinical gene editing

Unlocking the mechanism for clinical gene editing

UM171 binds the E3 ligase adaptor KBTBD4, driving degradation of CoREST1 and MYC to restore young HSC function — enhancing engraftment of gene-modified HSCs in sickle cell disease and enabling near-complete CD33 base editing.

The Leucegene program: multi-omic AML characterization

The Leucegene program: multi-omic AML characterization

Integration of RNA-seq, CITE-Seq, surfaceome, and exome data across ~700 primary AML specimens — one of the world’s best-characterized AML datasets for novel diagnostic, prognostic, and therapeutic targets.

Decoding AML genomic signatures

Decoding AML genomic signatures

Unifying markers across AML subgroups — MLL-rearranged (SPI1/RAS), APL (podoplanin), RUNX1-mutated (allele dosage), and TP53-mutated (3p deletion) — several now adopted in clinical practice.

Bridging genomics to therapeutics: the MISTIC platform

Bridging genomics to therapeutics: the MISTIC platform

Sustaining leukemia stem cells ex vivo enabled biologically accurate, large-scale chemical screens that directly correlate drug response with genomic and transcriptomic profiles to reveal actionable targets.

Mapping chemical vulnerabilities in AML

Mapping chemical vulnerabilities in AML

Matching AML genotypes to therapies: Venetoclax response predictors, PLK1 inhibitors, mubritinib (OXPHOS dependency), copper ionophores, and CCNK molecular glues / CDK8 inhibitors.

Expanding horizons: from blood to solid tumors

Expanding horizons: from blood to solid tumors

Vulnerabilities uncovered in AML — pyroptosis triggers, oxidative phosphorylation, and glycolysis — are shared with solid tumors, establishing a translational bridge with novel inhibitors in preclinical development.

30 years of mentorship: seeding global science leadership

30 years of mentorship: seeding global science leadership

132 trainees mentored across academia, biotech/CROs, funding agencies, and hospitals worldwide — including 22 PhDs, 23 MScs, 46 post-docs, 2 visiting scientists, and 39 summer students.

Advancing science, transforming patient care

Advancing science, transforming patient care

From mapping the epigenetic control of stem cells to bringing UM171 to global clinical trials, the lab remains dedicated to discovering actionable vulnerabilities in cancer and engineering the future of hematopoiesis.